Abstract Fri156: Mitochondrial permeability transition pore is a critical regulator of highly procoagulant platelet phenotypes

Le résumé fourni par la source

Background: Excessive platelet procoagulant activity, marked by sustained and high-magnitude phosphatidylserine (PS) externalization, promotes pathological thrombosis. While sustained cytosolic Ca 2+ elevation is required for this phenotype, the mitochondrial mechanisms that govern this process remain incompletely defined. The mitochondrial permeability transition pore (mPTP) has been implicated as a potential regulator of Ca 2+ overload and mitochondrial dysfunction in platelets; however, its causal role in regulating highly procoagulant platelet phenotypes has been difficult to establish, in part due to the lack of selective pharmacological tools. Existing approaches, such as cyclophilin D (CypD) inhibition with cyclosporine A, are confounded by off-target effects, limiting mechanistic interpretation. Aim: To determine whether mPTP opening functions as a critical regulatory target in the generation of highly procoagulant platelet phenotypes, using a newly developed series of cyclophilin D–independent small-molecule mPTP inhibitors (MC63, TR001, and TR002) as mechanistic tools. Results: Dual stimulation of washed human platelets with a GPVI agonist and thrombin induced mitochondrial depolarization, cytosolic Ca 2+ overload, and robust phosphatidylserine (PS) exposure. Pretreatment with MC63, TR001, or TR002 (10 µM) preserved mitochondrial membrane potential (~90% polarized vs. 16.8% in vehicle-treated platelets), attenuated Ca 2+ elevation, and markedly reduced PS exposure, as assessed by lactadherin binding (<10% vs. 47.5% in vehicle). These effects were confirmed by live-cell imaging of Annexin V–Alexa Fluor 488–stained platelets. In ex vivo whole blood under physiological shear (300 s -1 ), mPTP inhibition significantly suppressed procoagulant platelet formation while preserving granule secretion, integrin activation, and aggregation. To assess in vivo efficacy, we utilized a mouse cremaster arteriole laser injury model with intravital microscopy. Intravenous administration of MC63 (10 µg/g) resulted in a significant reduction in thrombus burden, decreasing median platelet accumulation by 59.7% and fibrin deposition by 70.8% compared to vehicle controls. Injury size was comparable between groups. Conclusion: These findings identify mPTP opening as a critical and druggable target controlling platelet commitment to highly procoagulant phenotypes and supporting mPTP inhibition as an antithrombotic strategy that may spare hemostatic platelet functions.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.